Deseret Mutual Benefit Administrators lessened its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 12.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,664 shares of the company’s stock after selling 2,171 shares during the period. Merck & Co., Inc. accounts for 0.8% of Deseret Mutual Benefit Administrators’ investment portfolio, making the stock its 18th largest position. Deseret Mutual Benefit Administrators’ holdings in Merck & Co., Inc. were worth $1,665,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Itau Unibanco Holding S.A. purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $39,000. Abich Financial Wealth Management LLC raised its position in shares of Merck & Co., Inc. by 121.8% in the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after purchasing an additional 179 shares during the period. Quarry LP purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at approximately $42,000. Strategic Financial Concepts LLC boosted its holdings in Merck & Co., Inc. by 1,475.6% in the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after buying an additional 32,832 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in Merck & Co., Inc. by 47.5% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after buying an additional 122 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.
Merck & Co., Inc. Stock Performance
NYSE MRK opened at $101.33 on Thursday. Merck & Co., Inc. has a 52-week low of $98.60 and a 52-week high of $134.63. The company has a fifty day moving average of $111.37 and a 200-day moving average of $120.33. The company has a market capitalization of $256.65 billion, a P/E ratio of 21.12, a P/E/G ratio of 1.46 and a beta of 0.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47.
Wall Street Analysts Forecast Growth
MRK has been the topic of several recent research reports. Wolfe Research upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Citigroup dropped their price objective on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Sanford C. Bernstein started coverage on Merck & Co., Inc. in a report on Thursday, October 17th. They set a “market perform” rating and a $115.00 target price for the company. Guggenheim lowered their price target on shares of Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Evercore ISI upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $129.93.
Read Our Latest Stock Analysis on MRK
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 2 Reasons To Like Coinbase After The Election, 1 to Still Avoid
- What is the Shanghai Stock Exchange Composite Index?
- Hunting for High-Yield Bargains? 2 REITs to Consider
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Fiserv Is Up 50% This Year and Can Go Another 50% Higher
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.